Mushrooms and GLP-1: Can Fungi Mimic the Ozempic Effect?

Incretin Hormones & Metabolic Syndrome

17% more GLP-1

Adding oyster mushroom powder to a single meal raised GLP-1 levels 17% higher than the same meal without mushroom, in a 2022 double-blind randomized controlled crossover trial.

Dicks et al., European Journal of Nutrition, 2022

14% lower NEFAs

free fatty acids in blood after the oyster mushroom meal

22 adults

enrolled in the only GLP-1-specific mushroom RCT

8.1g β-glucans

from 20g oyster mushroom powder, the dose that produced the effect

Dicks et al., European Journal of Nutrition, 2022

View as image ↗

The phrase "natural Ozempic" gets attached to a lot of things. Berberine, cinnamon, fiber supplements. Now mushrooms. When it comes to GLP-1, the hormone that drugs like Ozempic raise, mushrooms are the rare case where clinical trial data actually exists.

In 2022, researchers fortified a meal with 20 grams of oyster mushroom powder and gave it to 22 adults with impaired glucose tolerance. GLP-1 levels measured over the following hours were 17% higher than after the same meal without mushroom.^[1] That is a measurable effect on a real metabolic hormone. For a broader picture of how multiple mushroom species compare on blood sugar and metabolic health, see our guide to mushrooms and type 2 diabetes.

What the data does not show is that mushrooms work like semaglutide. The mechanism is different, the magnitude is different, and whether you respond at all depends on something neither you nor the mushroom fully controls: your gut microbiome.

How Mushrooms Actually Raise GLP-1 (It Is Not What Ozempic Does)

GLP-1 (glucagon-like peptide-1) is a hormone produced by specialized cells in the lining of the small intestine and colon. These cells, called L-cells, release GLP-1 after a meal. The hormone signals the pancreas to produce insulin, tells the stomach to slow its emptying, and informs the brain that food has arrived.

Drugs like semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) work by bypassing this entire process. They are synthetic molecules engineered to bind and activate GLP-1 receptors directly, at doses that produce sustained, pharmacological-level stimulation around the clock. The body's own GLP-1 production becomes largely irrelevant when a drug is occupying those receptors continuously.

Mushrooms work through the opposite end of the same system.

Oyster mushrooms and most other edible fungi contain beta-glucans, which are long chains of glucose linked together in a way that human digestive enzymes cannot break apart. These compounds pass through the stomach and small intestine largely intact, arriving at the colon where gut bacteria can ferment them. The fermentation products are short-chain fatty acids, primarily butyrate, propionate, and acetate. Those compounds bind to receptors on the intestinal wall called GPR41 and GPR43. Those receptors sit on L-cells. When they are activated, L-cells release GLP-1.

A 2022 systematic review confirmed that mushroom polysaccharides survive human digestion, reach the colon, and are fermented into short-chain fatty acids that activate this GPR41/43 signaling pathway to trigger GLP-1 secretion.^[4] A 2023 review extended that picture, mapping how specific gut bacteria (Lactobacillus, Bifidobacterium, and Akkermansia among them) proliferate in response to mushroom polysaccharides and how that bacterial growth drives the short-chain fatty acid production that ultimately activates L-cells.^[5]

So mushrooms raise GLP-1 by feeding the gut bacteria that produce the chemicals that trigger the body to make the hormone. Semaglutide raises GLP-1 receptor activation by skipping all of that and binding the receptor directly. The destination is partly the same hormone system. The path is entirely different.

For a deeper look at the full incretin system, including GIP, the second gut hormone that drugs like tirzepatide also target, see Mushroom Compounds and Incretin Hormones: GLP-1 and GIP Research.

The Clinical Trial That Put a Number on It: 17% More GLP-1 After a Mushroom Meal

The most specific human evidence for mushrooms raising GLP-1 comes from a 2022 double-blind randomized controlled crossover trial by Dicks and colleagues, published in the European Journal of Nutrition.^[1]

The setup: 22 adults with impaired glucose tolerance, meaning their blood sugar was elevated but not yet in the diabetic range, ate a standardized mixed meal on two separate occasions in random order. One version of the meal included 20 grams of oyster mushroom powder (Pleurotus ostreatus), delivering 8.1 grams of beta-glucans. The other version was the same meal without mushroom. Neither the participants nor the researchers measuring outcomes knew which was which.

After the mushroom-fortified meal, GLP-1 levels measured over the following hours were 17% higher. The improvement was calculated as the area under the hormone response curve, which captures the total hormonal signal over time rather than a single peak reading. The difference was statistically significant (P = 0.001).

A second finding from the same trial: circulating free fatty acids, measured as non-esterified fatty acids (NEFAs), were 14% lower after the mushroom meal (P = 0.026). Elevated free fatty acids are a marker of poor fat metabolism and a contributor to insulin resistance. Reducing them is a meaningful metabolic signal, though this finding receives almost no coverage in popular articles about this trial.

What the study did not show: a statistically significant reduction in blood glucose itself. The GLP-1 boost and the NEFA reduction were real, but the blood glucose response to the meal was not significantly different between conditions. This distinction matters. A hormone going up in blood does not automatically translate to glucose going down, especially in a single-meal test with 22 participants. The Dicks trial documented a physiological response to mushroom beta-glucans; it did not demonstrate a clinical glucose-lowering effect.

The Hunger Hormone Angle: What King Oyster Mushroom Did to Ghrelin

GLP-1 is one side of the appetite-hormone picture. Ghrelin is the other.

Ghrelin is produced mainly in the stomach. Levels rise when you are hungry and fall after eating. In obesity and metabolic disease, this post-meal drop is often blunted, leaving the body sending hunger signals even after sufficient food. GLP-1 drugs like semaglutide indirectly suppress ghrelin by slowing stomach emptying, which reduces the stomach's signal to produce the hormone.

A 2022 randomized controlled trial by Kleftaki and colleagues found that king oyster mushroom (Pleurotus eryngii, a close relative of the oyster mushroom) produced substantially greater ghrelin suppression than control in people with metabolically unhealthy obesity.^[3]

The same participants also showed improved postprandial blood glucose, reduced self-reported hunger scores, and increased fullness ratings compared to control. This is a more complete appetite-hormone picture than the Dicks trial provided: it was not just that one gut hormone went up, but that the hunger signal went down at the same time.

King oyster mushroom has a somewhat different beta-glucan profile than oyster mushroom, which may affect how fermentation unfolds in the colon and how much short-chain fatty acid is produced. Whether the ghrelin suppression came from the beta-glucan content specifically, the fiber, or the physical bulk of the mushroom slowing gastric emptying was not isolated in this trial. The Kleftaki study established the effect; the exact mechanism within the meal requires more work.

For a full look at how mushroom polysaccharides interact with the complete set of gut hormones that regulate satiety, see How Mushroom Polysaccharides Affect Gut Hormones That Regulate Appetite.

The Microbiome Problem: Why the GLP-1 Boost Is Not the Same for Everyone

The Dicks trial showed a 17% average increase in GLP-1. But averages can hide as much as they reveal.

A 2025 follow-up analysis by Klümpen and colleagues went back to the same 22 participants and asked a different question: did their gut microbiota composition before the meal predict how large a GLP-1 boost they got from the oyster mushroom powder?^[2]

The answer was yes, significantly.

Participants with lower microbial evenness, meaning their gut bacterial community was dominated by fewer types of bacteria rather than balanced across many, showed significantly greater GLP-1 responses to the mushroom meal (p = 0.012). The proposed mechanism connects directly to the beta-glucan fermentation pathway: beta-glucans are broken down into short-chain fatty acids by specific gut bacteria, and the efficiency of that fermentation depends on which bacteria are present and in what abundance.

Someone whose gut already contains plenty of the specific bacteria that ferment beta-glucans efficiently may convert the mushroom's compounds into short-chain fatty acids rapidly and get a strong GLP-1 response. Someone whose gut lacks those bacteria processes the same meal differently. The beta-glucan arrives at the colon but the biological machinery to convert it into the SCFA signal that activates L-cells is either absent or insufficient. The mushroom's active compounds reach their destination; the means to use them are not there.

A 2023 review of how mushroom polysaccharides interact with the gut microbiome confirmed that different bacterial ecosystems respond differently to the same polysaccharide inputs, which aligns with this individual variation.^[5] Other mushrooms beyond oyster also reshape the gut microbiome in ways that may affect appetite-hormone signaling over time, a topic explored in depth in Maitake and Metabolic Regulation: Beyond Blood Sugar to Full Metabolic Health.

The Klümpen analysis was exploratory. Twenty-two participants is too small a sample to draw firm conclusions about which specific microbiome profiles predict the strongest response. But it is the only study that has attempted to characterize why GLP-1 responses to mushroom consumption vary between individuals, and that makes it a genuinely novel finding in the field.

Mushrooms vs. Semaglutide: An Honest Look at Two Different Mechanisms

People searching for "natural Ozempic" often want to know whether mushrooms can replace a prescription drug. The evidence does not support that conclusion, and it is worth explaining why.

Semaglutide works by binding GLP-1 receptors directly. It is a synthetic molecule with a half-life measured in days, producing sustained receptor activation at concentrations many times higher than the body's own GLP-1 ever reaches. Weight loss trials have shown 15-20% body weight reduction over 68 weeks in people with obesity. That is a pharmacological effect from a pharmacological mechanism.

Mushrooms raise GLP-1 by 17% in the hours after a single meal, measured in 22 people with impaired glucose tolerance, when 20 grams of mushroom powder is added to that meal. That is a real biological response. It is not a pharmacological one.

The important distinction: semaglutide activates GLP-1 receptors continuously and powerfully, with concentrations that force sustained downstream effects on appetite, gastric emptying, and insulin secretion. Mushrooms stimulate L-cells to produce more GLP-1 in response to a meal, an effect that is meal-timed, fermentation-dependent, and constrained by the ceiling of what intestinal L-cells naturally produce.

What mushrooms do offer is a gut-mediated pathway that activates multiple appetite-hormone signals simultaneously. A 2019 review by Dubey and colleagues framed edible mushrooms as evidence-based tools for addressing both diabetes and obesity, not because of a single hormone, but because their beta-glucans, polysaccharides, and other compounds address multiple metabolic pathways at once.^[6] The GLP-1 effect is one part of a broader picture that includes ghrelin suppression, gut microbiome reshaping, and documented effects on blood lipids and insulin sensitivity across multiple species.

The honest frame is not that mushrooms work like Ozempic. It is that among the foods studied for metabolic hormone responses, mushrooms appear to activate the GLP-1 pathway more effectively than most, through a mechanism that is real and documented, at a scale that is smaller and more variable than a drug.

For a side-by-side look at the evidence across mushroom species for diabetes and metabolic health outcomes, see Comparing Mushroom Species for Diabetes Management: Which Has the Strongest Evidence?.

What the Research Can and Cannot Tell Us Yet

The evidence base for mushrooms and GLP-1 is genuinely promising, but narrow.

The core human trial enrolled 22 people and measured a single-meal response. The result was statistically significant and biologically plausible, but a sample of 22 does not allow population-level conclusions, and no trial has yet measured whether repeated daily mushroom consumption over weeks or months produces sustained GLP-1 elevation. The mechanism from lab and animal models is well-documented; the long-term human hormonal response to daily mushroom intake has not been mapped.

The Kleftaki ghrelin finding adds a second appetite-hormone signal, but comes from a single trial in a specific population of metabolically unhealthy obese individuals. Whether the ghrelin suppression applies broadly or is more pronounced in people whose ghrelin regulation is already impaired remains unknown.

The Klümpen 2025 microbiome finding suggests that aggregated trial results may obscure a wide range of individual responses, from strong responders who see substantial GLP-1 increases to near-non-responders who get little effect. The microbiome characteristics that predict which group a given person falls into have not been characterized in a larger study.

What is well-established is the mechanistic chain: mushroom polysaccharides survive human digestion, reach the colon, are fermented by gut bacteria into short-chain fatty acids, and those short-chain fatty acids activate GPR41/43 receptors on L-cells to trigger GLP-1 release. The human evidence shows this pathway is active in response to a mushroom meal. What is not established is how large the effect is across different populations, mushroom preparations, doses, and lengths of time.

For how this GLP-1 signal fits into the broader metabolic picture, including what mushrooms do for all five criteria of metabolic syndrome, see Mushrooms and Metabolic Syndrome: Targeting All Five Criteria.

The Bottom Line

Oyster mushroom beta-glucans raised GLP-1 by 17% in a 2022 clinical trial by triggering the body's own hormone production through gut fermentation, which is a fundamentally different process from how GLP-1 drugs like semaglutide work. A 2025 analysis of the same participants found that gut microbiome composition before the meal predicted how large the GLP-1 response would be, suggesting the effect is not uniform across individuals. The evidence base is real but currently limited to small, single-meal studies; long-term effects on body weight through the mushroom-GLP-1 pathway remain untested.

Frequently Asked Questions

Do mushrooms boost GLP-1?

Yes. A 2022 double-blind crossover trial found that a meal fortified with 20 grams of oyster mushroom powder raised GLP-1 levels by 17% over the following hours compared to the same meal without mushroom (Dicks et al.). The effect works through gut fermentation of beta-glucans into short-chain fatty acids, which activate L-cells in the intestinal lining to secrete GLP-1. Whether any given person responds depends partly on their gut microbiome composition.

Can beta-glucans work like Ozempic?

Not in the same way. Beta-glucans stimulate the body's own GLP-1 production by feeding gut bacteria that generate short-chain fatty acids, which then signal intestinal L-cells to release GLP-1. Semaglutide (Ozempic) bypasses that entire process, binding GLP-1 receptors directly at pharmacological doses that produce sustained, continuous activation. The two approaches touch the same hormone system through completely different mechanisms and at very different scales of effect.

Which mushrooms naturally increase GLP-1?

The only mushroom with direct human trial evidence for raising GLP-1 is oyster mushroom (Pleurotus ostreatus), based on the 2022 Dicks trial. King oyster mushroom (Pleurotus eryngii) showed improved appetite-hormone responses including ghrelin suppression in a separate 2022 RCT (Kleftaki et al.). Other beta-glucan-rich species such as maitake, reishi, and shiitake activate the same gut fermentation pathway in animal and mechanistic studies, but direct GLP-1 measurements from human trials for those species are lacking. Maitake's clinical blood sugar evidence is covered in depth in Maitake and Type 2 Diabetes: The SX-Fraction Clinical Trials.

Are mushrooms a natural alternative to semaglutide?

No, based on current evidence. Semaglutide produces 15-20% body weight reduction in clinical trials by directly and continuously activating GLP-1 receptors at pharmacological concentrations. Mushrooms raised GLP-1 by 17% after a single meal in a small trial of 22 people. These are different scales of effect achieved through different mechanisms. Mushrooms address multiple metabolic signals simultaneously through a gut-fermentation pathway, but no evidence shows they produce the kind of sustained weight loss seen with GLP-1 drugs.

What foods naturally stimulate GLP-1?

Foods that gut bacteria ferment into short-chain fatty acids tend to stimulate GLP-1 release from intestinal L-cells. High-fiber foods including mushrooms, oats, legumes, and resistant-starch-rich whole grains all share this gut-fermentation mechanism. Mushrooms are notable because their beta-glucan structures are particularly resistant to human digestion, maximizing the amount that reaches the colon for bacterial fermentation. Protein and certain fats also stimulate some GLP-1 release through separate pathways, though the magnitude from those routes differs.

How do mushrooms affect appetite hormones?

Mushrooms appear to affect at least two appetite hormones through gut-mediated pathways. GLP-1, which signals fullness and slows stomach emptying, rose by 17% after an oyster mushroom meal in people with impaired glucose tolerance (Dicks et al., 2022). Ghrelin, the hormone that drives hunger and typically drops after eating, was significantly more suppressed by king oyster mushroom than by control food in a 2022 RCT of obese subjects (Kleftaki et al.). Both effects are meal-timed and depend on gut fermentation of mushroom polysaccharides.

Sources & References

1. 1RTHM-00753·Dicks, Lisa et al. (2022). “Fortifying a meal with oyster mushroom powder beneficially affects postprandial glucagon-like peptide-1, non-esterified free fatty acids and hunger sensation in adults with impaired glucose tolerance: a double-blind randomized controlled crossover trial..” European journal of nutrition.Study breakdown →PubMed →↩
2. 2RTHM-02111·Klümpen, Linda et al. (2025). “GLP-1 Responses to a Single Meal Fortified With Oyster Mushroom Powder in Adults With Impaired Glucose Tolerance Depend on the Gut Microbiota Composition Before the Meal..” Molecular nutrition & food research.Study breakdown →PubMed →↩
3. 3RTHM-01551·Kleftaki, Stamatia-Angeliki et al. (2022). “Pleurotus eryngii improves postprandial glycaemia, hunger and fullness perception, and enhances ghrelin suppression in people with metabolically unhealthy obesity..” Pharmacological research.Study breakdown →PubMed →↩
4. 4RTHM-01577·Ma, Gaoxing et al. (2022). “Health benefits of edible mushroom polysaccharides and associated gut microbiota regulation..” Critical reviews in food science and nutrition.Study breakdown →PubMed →↩
5. 5RTHM-01835·Zhao, Jiahui et al. (2023). “The Interaction between Mushroom Polysaccharides and Gut Microbiota and Their Effect on Human Health: A Review..” Biology.Study breakdown →PubMed →↩
6. 6RTHM-01051·Dubey, Sushil K et al. (2019). “Role of edible mushroom as a potent therapeutics for the diabetes and obesity..” 3 Biotech.Study breakdown →PubMed →↩